R R

What Is Oral Bioavailability?

Oral bioavailability is the rate and extent to which an active drug from a swallowed product is absorbed and becomes available in the systemic circulation or at its site of action. Absolute oral bioavailability commonly compares exposure after an oral dose with exposure after an intravenous dose. A value of 50 percent means that systemic exposure reflects about half of the dose after adjustment for dose size. Bioavailability includes the effects of both gastrointestinal absorption and presystemic loss.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Oral Bioavailability?

Oral bioavailability is the rate and extent to which an active drug from a swallowed product is absorbed and becomes available in the systemic circulation or at its site of action. Absolute oral bioavailability commonly compares exposure after an oral dose with exposure after an intravenous dose. A value of 50 percent means that systemic exposure reflects about half of the dose after adjustment for dose size. Bioavailability includes the effects of both gastrointestinal absorption and presystemic loss.

read more about oral bioavailability ...

Copy this HTML:

Copy HTML Copied!

What Determines Oral Bioavailability?

A drug must be released from its dosage form, dissolve, remain stable, cross the intestinal lining, and avoid excessive metabolism before reaching systemic circulation. Solubility, permeability, gastric emptying, intestinal motility, transporters, enzymes, and liver blood flow can affect this process. The formulation, particle size, coating, salt form, and manufacturing method also influence exposure. Patient age, illness, surgery, genetics, and other medicines can create additional variation.

How Does First-Pass Metabolism Affect Bioavailability?

After intestinal absorption, many drugs enter the portal circulation and pass through the intestinal wall and liver before reaching the rest of the body. Enzymes and transporters can remove or metabolize part of the dose during this first pass. Extensive first-pass metabolism lowers oral bioavailability even when intestinal absorption is good. Liver disease, interacting medicines, or portal-systemic shunting can change this effect.

How Is Oral Bioavailability Measured?

Pharmacokinetic studies measure drug concentrations in blood over time after administration. The area under the concentration-time curve reflects the extent of systemic exposure, while peak concentration and time to peak help describe the rate of absorption. Absolute bioavailability compares dose-adjusted oral and intravenous exposure. Relative bioavailability compares two nonintravenous products or formulations.

What Can Change Oral Bioavailability?

Food can increase, decrease, delay, or have little effect on absorption depending on the medicine and formulation. Antacids, mineral supplements, acid-suppressing drugs, enzyme inhibitors, enzyme inducers, and transporter modifiers can change exposure. Crushing or opening a modified-release product can alter release and bioavailability. Product-specific instructions should be followed because equal milligram doses do not always produce equal systemic exposure across formulations.

Frequently Asked Questions About Oral Bioavailability

Is oral bioavailability the same as absorption?

No. Absorption describes entry from the gastrointestinal tract, while bioavailability also accounts for drug lost through intestinal or hepatic first-pass processes.

Does 100 percent oral bioavailability mean the drug works completely?

No. It means systemic exposure after oral administration is essentially complete relative to the reference route. Clinical response still depends on distribution, target sensitivity, dose, and other factors.

Why is intravenous bioavailability considered 100 percent?

An intravenous dose enters the systemic circulation directly without an absorption step or first-pass loss. It is therefore used as the reference for absolute bioavailability.

Is bioavailability the same as bioequivalence?

No. Bioavailability describes the rate and extent of drug availability from a product. Bioequivalence compares whether two products have sufficiently similar bioavailability under defined conditions.

References

Bioavailability Studies Submitted in NDAs or INDs ? General Considerations. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-studies-submitted-ndas-or-inds-general-considerations. Date Accessed August 6, 2026.

Assessing the Effects of Food on Drugs in INDs and NDAs ? Clinical Pharmacology Considerations. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology-considerations. Date Accessed August 6, 2026.

Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug. Date Accessed August 6, 2026.

Drug Bioavailability. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK557852/. Date Accessed August 6, 2026.

First-Pass Effect. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK551679/. Date Accessed August 6, 2026.